Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Payables (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Payables for 6 consecutive years, with $879000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 87.96% to $879000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $879000.0, a 87.96% decrease, with the full-year FY2024 number at $8.0 million, up 239.94% from a year prior.
  • Payables was $879000.0 for Q3 2025 at Mereo BioPharma, down from $1.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.8 million in Q4 2022 to a low of $879000.0 in Q3 2025.
  • A 5-year average of $5.7 million and a median of $5.2 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: surged 399.25% in 2022, then plummeted 87.96% in 2025.
  • Mereo BioPharma's Payables stood at $3.4 million in 2021, then skyrocketed by 399.25% to $16.8 million in 2022, then crashed by 86.05% to $2.3 million in 2023, then soared by 239.94% to $8.0 million in 2024, then tumbled by 88.98% to $879000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Payables are $879000.0 (Q3 2025), $1.1 million (Q2 2025), and $2.9 million (Q1 2025).